Prostate cancer (PCa) is the most commonly diagnosed noncutaneous malignancy and
second leading cause of cancer-related deaths in US males. Clinically, locally confined …

The androgen receptor (AR) signaling axis plays a critical role in the development, function
and homeostasis of the prostate. The classical action of AR is to regulate gene …

Prostate cancer (PCa) is the most frequently diagnosed non-cutaneous malignancy and
leading cause of cancer mortality in men. At the initial stages, prostate cancer is dependent …

In last years several improvements have been made in the management of prostate cancer
(PCa). Androgen receptor (AR) is considered the main driver in PCa growth and progression …

Despite aggressive treatment for localized cancer, prostate cancer (PC) remains a leading
cause of cancer-related death for American men due to a subset of patients progressing to …

Prostate cancer is the most common cancer and the second leading cause of death from
cancer in males in most Western countries. Prostate cancer has an exquisite sensitivity to …

Patients with localized prostate cancer (PCa) have several therapeutic options with good
prognosis. However, survival of patients with high-risk, advanced PCa is significantly less …

Prostate cancer (PCa) is one of the most common malignancies found in males. The
development of PCa involves several mutations in prostate epithelial cells, usually linked to …

Prostate cancer (CaP) remains the second leading cause of cancer deaths in Western men.
These deaths occur because metastatic CaP acquires resistance to available treatments …

Prostate cancer (PCa) progression relies on androgen receptor (AR) action. Preventing AR's
ligand-activation is the frontline treatment for metastatic PCa. Androgen deprivation therapy …